Recida Therapeutics

Recida Therapeutics is a biopharmaceutical company dedicated to developing new therapies for severe antibiotic-resistant infections. Recida's lead program, RC-01, is a novel IND-stage LpxC inhibitor aimed at treating multidrug-resistant Gram-negative bacterial infections. Recida is led by an experienced team of pharmaceutical and anti-infective executives committed to improving outcomes for patients with multidrug resistance and other difficult-to-treat infections.